Guardant360

Guardant360®—the most clinically validated liquid biopsy, now 10 times more powerful

Guardant360®, the ultimate power behind cancer testing, is now enhanced by Guardant Infinity—the first and only commercially available platform that integrates both epigenomics and genomics to transform precision oncology.

Key features for Guardant360

  • 739 Genes:  The test analyzes a comprehensive panel of 739 genes for a thorough evaluation.

  • Tumor Fraction: It accurately quantifies disease burden based on methylation, with variants detected as low as 0.001% MAF.

  • Turnaround Time: With a rapid turnaround of just 7 days, clinicians can make fast treatment decisions.

  • Cost: The test is available at no cost for over 92% of patients, even before the Guardant Access Program is applied.

 

Book Appointment

Guardant360®: Comprehensive Biomarker Coverage

Guardant360 covers genomic biomarkers recommended in clinical guidelines across various cancer types:

  • Lung Cancer: ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK1, NTRK2, NTRK3, RET, ROS1
  • Breast Cancer: AKT1, BRCA1, BRCA2, ERBB2, ESR1, NTRK1, NTRK2, NTRK3, PALB2, PIK3CA, PTEN, RET, MSI, TMB
  • Colorectal Cancer: BRAF, ERBB2, KRAS, NRAS, NTRK1, NTRK2, NTRK3, POLD1, POLE, RET, MSI
  • IProstate Cancer: ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MLH1, MRE11, NBN, PALB2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, TP53, MSI, TMB

Transformative Benefits of Guardant360®

  • Longer Overall Survival: Patients with non-small cell lung cancer (NSCLC) who receive genomic profiling results experience longer overall survival.
  • Identification of Treatment-Resistant Mutations: Guardant360 can identify mutations that confer treatment resistance, potentially occurring at any time during therapy.
  • Insurance Coverage: Guardant360 tests are covered for over 300 million lives across major insurers, including Aetna, Anthem, Cigna, United Healthcare, and others.

Important Information About Guardant360

Guardant360 is a Laboratory Developed Test (LDT) established by Guardant Health Clinical Laboratory in Redwood City, CA, recognized for its high-complexity clinical testing under CLIA certification. Although it has not received FDA approval, the test offers valuable insights by analyzing mutant allele fraction (MAF), microsatellite instability (MSI), and tumor mutation burden (TMB). The features of Guardant360 may vary depending on the specific product configuration. Importantly, over 92% of patients are likely to face no cost for the test, enhancing accessibility.